PANACEA consortium to increase global access to NMR spectroscopy
The Pan-European Solid-State NMR Infrastructure for Chemistry-Enabling Access will offer researchers access to over 30 NMR spectrometers.
List view / Grid view
The Pan-European Solid-State NMR Infrastructure for Chemistry-Enabling Access will offer researchers access to over 30 NMR spectrometers.
German, Norwegian and British scientists have identified molecular targets for therapies that could prevent breast cancer recurrence.
The La Jolla Institute for Immunology and Brigham and Women's Hospital will collaborate to develop a pan-coronavirus vaccine.
A new method, called synapse for T-cell activation (synTac), can attack HIV-infected T cells and may be a new cure for HIV and other diseases.
Activating the protein channel TRPML1 induced selective melanoma cell death while sparing normal cells, suggesting a potential pathway for new cancer therapies.
Scientists have created a nanofibre-based sheet to control and direct the migration of cells, possibly leading to brain tumour therapies.
Washington University will receive $7.5 million from the NIH to study senescent cells for treatments against age-related diseases.
Scientists have identified potential cancer drugs to treat pulmonary hypertension using experimental and computational approaches.
In a new study, a calorie-restricted diet significantly reduced tumour growth in mouse models, suggesting new possibilities for cancer therapies.
The statistical method known as maximum entropy could improve cryogenic electron microscopy (cryo-EM) for more effective drug treatments.
The antimicrobial hygromycin A was shown to clear Lyme disease in mice, representing a promising therapeutic against the disease.
Scientists have developed a novel technique for the targeted clearance of senescent cells to improve treatments for ageing and other conditions.
Mammalian target of rapamycin complex 2 (mTORC2) was found to prevent brain damage in mice infected with herpes simplex virus 1 (HSV-1).
Medicenna's IL-2 super-agonist, MDNA11, successfully induced antitumour cells in animal models, a pre-clinical study has revealed.
New dendritic hydrogels were tested against several infectious bacteria and could be used as an an antibiotic-free treatment in the future.